The When and How of Implementing New Anti-Neutrophil Therapies Into Standard Clinical Practice
Host: Pamela J. McShane, MD
\n\n Host: Gregory Tino, MD
\n\n Host: Ashwin Basavaraj, MD
\n\n\n \n
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.